Top Markets
#1 QuantixAI QuantixAI +34.96%
#2 Zora Zora +32.02%
#3 AI XOVIA AI XOVIA +26.43%
#4 Helium Helium +21.02%
#5 0G 0G +20.83%
#6 SAFEcoin SAFEcoin +20.56%
#7 Full Moon Full Moon +19.89%
#8 Merlin's Seal BTC Merlin's Seal BTC +16.54%
#9 Axelar Axelar +14.53%
#10 VVS Finance VVS Finance +13.71%
Coin of the day
QuantixAI QuantixAI
設定
言語
日本
通貨
USD
テーマ
CTI BioPharma Corp. CTI BioPharma Corp.

CTI BioPharma Corp.

CTIC
株式のランク #12604
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
株価
$9.09
最終同期: 2023-06-23
時価総額
$567.77M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 CTI BioPharma Corp. (CTIC)

カテゴリー

Healthcare
CTI BioPharma Corp.（CTIC）のP/S比率
2026 時点のP/S比率 TTM: 0
CTI BioPharma Corp. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
CTI BioPharma Corp. の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
年 P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH